Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression

European Journal of Nuclear Medicine

Volumn 23, Issue 8, 1996, Pages 980-986

  Moretti, Jean Luc ^a,e   Azaloux, Hervé ^b   Boisseron, Dominique ^b   Kouyoumdjian, Jean Claude ^c   Vilcoq, Jacques ^d  

^a Section of Radiology   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d INSTITUT CURIE   (France)

^e AVICENNE HOSPITAL   (France)

Author keywords

Breast cancer; Multidrug resistance; P glycoprotein; Sestamibi

Indexed keywords

CA 15-3 ANTIGEN; ESTROGEN RECEPTOR; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CLINICAL ARTICLE; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MAMMOGRAPHY; MULTIDRUG RESISTANCE; ONCOGENE NEU; PROTEIN EXPRESSION; SCINTISCANNING;

EID: 0029763242     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01084375     Document Type: Article

References (39)

1. 99m MIBI SPECT [abstract]. J Nucl Med 1987; 28: 562.
2. 99m-hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions of the lungs. Clin Nucl Med 1989; 14: 333-340.
3. 99m MIBI TI-201 uptake in bronchial carcinoma [abstract]. J Nucl Med 1989; 30: 845.
4. O'Tuama LA, Packard AB, Treves ST. SPECT imaging of pediatric brain tumor with hexakis (methoxyisobutylisonitrile) technetium (I). J Nucl Med 1990; 31: 2040-2041.
5. Waxman AD, Ramanna L, Memsic LD, Foster CE, Silberman AW, Gleischman SH, Brenner RJ, Brachman MB, Kuhar CJ, Yadegar J. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993; 34: 18-23.
6. Cimitan M, Volpe R, Candiani E, Gusso G, Ruffo R, Borsatti E, Massarut S, Rossi C, Morassut S. The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. Eur J Nucl Med 1995; 22: 1110-1117.
7. Scopinaro F, Schillaci O, Scarpini M, Mingazzini PL, Di Macio L, Banci M, Danieli R, Zerilli M, Limiti MR, Centi Colella A. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21: 984-987.
8. 99m sestamibi myocardial retention. Eur J Nucl Med 1993; 20: 20-25.
9. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
10. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994; 21: 432-436.
11. m-MIBI: a comparative study with mammography and ultrasonography. Nucl Med Commun 1994; 15: 604-612.
12. Waxinan A, Nagaraj N, Ashok G, Khan S, Yadegar J, Memsic L, Silberman A, Jochelson M, Katz R, Phillips E. Sensitivity and specificity of Tc-99m methoxy isobutyl isonitrile (MIBI) in the evaluation of primary carcinoma of the breast: comparison of palpable and non-palpable lesions with mammography. [Abs] J Nucl Med 1994; 35: 22.
13. Lastoria S, Varrella P, Mainolfi C, Vergara E, Maurea S, Acampa W, Piccolo S, Salvatore M. Tc-99m Sesta MIBI scintigraphy in the diagnosis of primary breast cancer. [Abs] J Nucl Med 1994; 35: 22.
14. Khalkhali I, Cutrone J, Mena I, Diggles L, Venegas R, Vargas M. Clinical and pathologic follow-up of 100 patients (pts) with breast lesions studied with scintimammography. [Abs] J Nucl Med 1994; 35: 22.
15. Juliano R.L., Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
16. Bourhis J, Riou G. Bénard J. Expression de la p-glycoprotein 170 (GP 170) et résistance à la chimiothérapie des cancers humains. Bull Cancer (Paris) 1990; 77: 957-965.
17. Bellamy WT, Dalton WS, Dorr RT. The clinical relevance of multidrug resistance. Cancer Invest 1990; 8: 547-562.
18. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989; 60: 815-818.
19. Kieth WN, Stallard S, Brown R. Expression of mdrl and gst-p in human breast tumours: comparison to in vitro chemosensitivity. Br J Cancer 1990; 61: 712-716.
20. Kacinski BM, Yee LD, Carter D, Quantitalion of tumor cell expression of the P-glycoprotein (mdrl) gene in human breast carcinoma clinical specimens. Cancer Bull 1989; 41: 44-48.
21. Kacinski BM, Yee LD, Carter D, Li D, Kuo MT. Human breast carcinoma cell levels of MDR-l (P-glycoprotein) correlate in vivo inversely and reciprocally with tumor progesterone receptor content. Cancer Commun 1989; 1: 1-6.
22. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
23. Duran Cordobes M, Starzec A, Delmon-Moingeon L, Blanchot C. Kouyoumdjian JC, Prévost G, Caglar M, Moretti JL. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with gene expression. J Nucl Med 1996; 37: 286-289.
24. Sluyser M, Hoefnagel CA. Breast carcinomas detected by thallium-201 scintigraphy. Cancer Lett 1988; 40: 161-168.
25. Khalkhali I, Cutrone J, Mena I, Diggles L, Venegas R, Vargas H, Jackson B, Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological followup. J Nucl Med 1995; 36: 1784-1789.
26. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1741.
27. Hayes JD, Wolf CR. Molecular mechanisms of drug resistance, Biochem J 1990: 272: 281-295.
28. Pinedo HM, Longo D, Chabner E. Cancer chemotherapy and biological response modifiers. Annual 12. Amsterdam: Elsevier, 1991.
29. Biedler JL, Riehm H. Cellular resistance to actinomycin? Chinese hamster cells in vitro: cross resistance. radioautographic and cytogenetic studies. Cancer Res 1970; 30: 1174-1184.
30. Simon SM, Schindlert M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 3497-3504.
31. Wishart GC, Plumb JA, Going JJ, et al. P-glycoprotein expression in primary breast cancer detected by immunochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761.
32. Ro J, Sahin A, Ro JY, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1991; 21: 787-791.
33. Sanfilippo O, Ronchi E, De Marco C, Difronzo G, Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Kur J Cancer 1991; 27: 155-158.
34. Verelle P, Mcissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance of P-glycoprotein in breast carcinoma. J Nutl Cancer Inst 1991; 3: 111-116.
35. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of mdrl (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-7164.
36. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991; 51: 2720-2726.
37. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629-1635.
38. Linn SC, Van Ark-Otle J, Kuiper CM, Van der Valk P, Vermorken JB, Pinedo HM, Giaccone G. Expression of multidrug resistance (MDR) genes in normal breast tissue, primary and advanced breast cancer and treatment outcome. Anti-Cancer Drugs 1994; 5: 56.
39. Mitze M, Beck T, Weikel W, Brumm C, Knapstein PG. Immunohistochemical detection of p-170 glycoprotein in human breast cancer tissue. J Cancer Res Clin Oncol 1991; 117: 93.